177 related articles for article (PubMed ID: 8735795)
1. Prophylaxis and continuous infusion for hemophilia: can we afford it?
Aledort LM; Bohn RL
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S35-7. PubMed ID: 8735795
[TBL] [Abstract][Full Text] [Related]
2. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
Goldsmith JC
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
[TBL] [Abstract][Full Text] [Related]
3. Experience with prophylaxis in Sweden.
Nilsson IM
Semin Hematol; 1993 Jul; 30(3 Suppl 2):16-9. PubMed ID: 8367738
[No Abstract] [Full Text] [Related]
4. Secondary prophylaxis in an adult patient with severe haemophilia A. Factor VIII consumption and effectiveness.
Schlenkrich S; Schubert C
Hamostaseologie; 2013 Aug; 33(3):241-4. PubMed ID: 23435748
[TBL] [Abstract][Full Text] [Related]
5. Relationship between factor VIII replacement therapy and joint damage in severe haemophilia.
Lowe GD
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S3-5. PubMed ID: 9351528
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness--can it be measured?
Bohn RL; Avorn J
Semin Hematol; 1993 Jul; 30(3 Suppl 2):20-3. PubMed ID: 8367739
[No Abstract] [Full Text] [Related]
7. Family issues in continuous infusion therapy with factor VIII.
Manco-Johnson MJ
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S21-5. PubMed ID: 8735793
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of factor VIII for surgery and major bleeding.
Hay CR; Doughty HI; Savidge GF
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
[TBL] [Abstract][Full Text] [Related]
9. Experience with prophylaxis in Germany.
Schramm W
Semin Hematol; 1993 Jul; 30(3 Suppl 2):12-5. PubMed ID: 8367737
[No Abstract] [Full Text] [Related]
10. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Manco-Johnson MJ; Abshire TC; Shapiro AD; Riske B; Hacker MR; Kilcoyne R; Ingram JD; Manco-Johnson ML; Funk S; Jacobson L; Valentino LA; Hoots WK; Buchanan GR; DiMichele D; Recht M; Brown D; Leissinger C; Bleak S; Cohen A; Mathew P; Matsunaga A; Medeiros D; Nugent D; Thomas GA; Thompson AA; McRedmond K; Soucie JM; Austin H; Evatt BL
N Engl J Med; 2007 Aug; 357(6):535-44. PubMed ID: 17687129
[TBL] [Abstract][Full Text] [Related]
11. Review of pumps for continuous infusion of coagulation factor concentrates: what are the options?
Martinowitz U; Schulman S
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S27-33. PubMed ID: 8735794
[TBL] [Abstract][Full Text] [Related]
12. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion.
Morfini M; Messori A; Longo G
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S11-4. PubMed ID: 8735791
[TBL] [Abstract][Full Text] [Related]
14. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
Lindvall K; Astermark J; Björkman S; Ljung R; Carlsson KS; Persson S; Berntorp E
Haemophilia; 2012 Nov; 18(6):855-9. PubMed ID: 22681244
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis in haemophilic children.
Liesner RJ
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia.
van den Berg HM; Fischer K; Mauser-Bunschoten EP; Beek FJ; Roosendaal G; van der Bom JG; Nieuwenhuis HK
Br J Haematol; 2001 Mar; 112(3):561-5. PubMed ID: 11260054
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic factor replacement in hemophilia.
Carcao MD; Aledort L
Blood Rev; 2004 Jun; 18(2):101-13. PubMed ID: 15010149
[TBL] [Abstract][Full Text] [Related]
19. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
Roosendaal G; Lafeber FP
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
[TBL] [Abstract][Full Text] [Related]
20. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
